Prognostic value of the <i>TP53</i> mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX.

ABSTRACT:

Background

KRAS, TP53, CDKN2A, and SMAD4 have been the main driver mutations in pancreatic ductal adenocarcinoma (PDAC). Studies on the clinical significance and treatment response to 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) regimen in terms of the presence of these mutations remain inconclusive.

Objectives

This study aimed to compare the survival outcome and response to FOLFIRINOX chemotherapy based on the presence of four driver mutation genes.

Design

A multi-center retrospective study conducted at two tertiary medical centers.

Methods

This study analyzed PDAC patients who were treated with FOLFIRINOX chemotherapy as the initial treatment. Tumor specimens were analyzed by a targeted next-generation seque

SUBMITTER: Kim MK 

PROVIDER: S-EPMC11500227 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature